Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04454281 · ClinicalTrials.gov registry record · Phase 1
Topical Naloxone to Diagnose Ocular Pain
A Phase 1 study of Neuropathic Pain and Dry Eye Syndromes, sponsored by Seema Capoor.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT04454281: Completed Phase 1 study of Neuropathic Pain and Dry Eye Syndromes, sponsored by Seema Capoor.
NCT04454281 is a Phase 1 study of Neuropathic Pain and Dry Eye Syndromes that has completed, run by Seema Capoor. The registered enrollment target is 1 participants, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04454281, a Phase 1 study of Neuropathic Pain and Dry Eye Syndromes, has completed, sponsored by Seema Capoor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronic ocular neuropathic pain may be misdiagnosed as dry eye disease. Our study aims to identify a population with previous monocular trauma and dry eye symptoms and differentiate neuropathic from dry eye pain using topical corneal naloxone hydrochloride.
Primary Outcome
The pain response is graded using a Visual Analog Scale (VAS) survey. It is graded 1-10; 10 indicates the most severe pain.
Conditions Studied
Interventions
- DRUG Naloxone Hydrochloride 0.4 MG/ML
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2020-12-03 |
| Phase | Phase 1 |
What the finished NCT04454281 record still lists
NCT04454281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Neuropathic Pain appearing as the primary indexed condition, and to 1 intervention - of which Naloxone Hydrochloride 0.4 MG/ML is the first listed.
NCT04454281 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT04454281 about?
NCT04454281 is a clinical study titled "Topical Naloxone to Diagnose Ocular Pain". Chronic ocular neuropathic pain may be misdiagnosed as dry eye disease. Our study aims to identify a population with previous monocular trauma and dry eye symptoms and differentiate neuropathic from dry eye pain using topical corneal naloxone hydrochloride.
What is the current status of trial NCT04454281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-10-01. Estimated completion is 2020-12-03.
What conditions does trial NCT04454281 study?
This clinical trial studies the following conditions: Neuropathic Pain, Dry Eye Syndromes.
What interventions are being tested in trial NCT04454281?
The interventions under investigation include: Naloxone Hydrochloride 0.4 MG/ML (DRUG).
Who is sponsoring clinical trial NCT04454281?
This trial is sponsored by Seema Capoor, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04454281 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04454281's enrollment target sits among peer trials
1 36th of 35 the lowest of 35 other Neuropathic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuropathic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
RECRUITING · Phase 1
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
Effects of Smoked Marijuana on Neuropathic Pain
COMPLETED · Phase 1
-
Tariquidar-ondansetron Combination in Neuropathic Pain
COMPLETED · Phase 1
-
Virtual Reality (VR) Self-Hypnosis Software
RECRUITING · NA
-
Neuropathic Pain and Operant Conditioning of Cutaneous Reflexes After SCI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI